Company intelligence / Profile preview

TS Dyne

Waltham, Massachusetts, United Statesdyne-tx.com ↗

Ownership: Private
Employees: ~201
Development stage: Phase 1

Overview

Dyne Therapeutics has initiated clinical programs in myotonic dystrophy type 1 and Duchenne muscular dystrophy. The company also has preclinical programs in facioscapulohumeral muscular dystrophy and Pompe disease. Early data supports targeted delivery to muscle and CNS using its FORCE™ platform.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Antisense oligonucleotideSmall moleculeBiologic
Industry: Biotech

Drug pipeline

3 assets

DYNE-101

Phase 1

Indications: Myotonic dystrophy type 1

2 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on TS Dyne.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TS Dyne.

Explore the full profile